This company has been marked as potentially delisted and may not be actively trading. Verve Therapeutics (VERV) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock Get the Latest News and Ratings for VERV and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Verve Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VERV Analyst Ratings Over TimeTypeCurrent Forecast8/28/24 to 8/28/251 Month Ago7/29/24 to 7/29/253 Months Ago5/30/24 to 5/30/251 Year Ago8/29/23 to 8/28/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy3 Buy rating(s)3 Buy rating(s)6 Buy rating(s)5 Buy rating(s)Hold6 Hold rating(s)6 Hold rating(s)0 Hold rating(s)1 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$14.57$14.57$25.75$25.20Forecasted Upside30.92% Upside30.92% Upside481.26% Upside329.30% UpsideConsensus RatingHoldHoldBuyModerate Buy VERV Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History VERV Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Verve Therapeutics Stock vs. The CompetitionTypeVerve TherapeuticsMedical CompaniesS&P 500Consensus Rating Score 2.33 2.78 2.53Consensus RatingHoldModerate BuyModerate BuyPredicted Upside30.92% Upside15,782.23% Upside10.41% UpsideNews Sentiment RatingNeutral NewsSee Recent VERV NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails6/27/2025BMO Capital Markets4 of 5 starsKostas BiliourisSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$20.00 ➝ $13.50+19.63%6/18/2025Jefferies Financial Group2 of 5 starsRoger SongSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$28.00 ➝ $11.00-3.34%6/18/2025Lifesci Capital3 of 5 starsCory JubinvilleSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$12.00+5.45%6/18/2025HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingMitchell KapoorSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$13.50+18.63%6/17/2025William BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingMyles MinterSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Market Perform6/17/2025Canaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingWhitney IjemSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$39.00 ➝ $13.00+18.45%4/15/2025GuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingEtzer DaroutSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost TargetBuy ➝ Buy$18.00 ➝ $24.00+373.19%4/15/2025Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingRick BienkowskiSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight3/4/2025Royal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLuca IssiSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower TargetOutperform ➝ Outperform$17.00 ➝ $15.00+160.78%4/3/2024Stifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetBuy ➝ Buy$56.00 ➝ $40.00+378.47% Get the Latest News and Ratings for VERV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:19 PM ET. VERV Forecast - Frequently Asked Questions What is Verve Therapeutics' forecast for 2025? According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Verve Therapeutics is $14.57, with a high forecast of $24.00 and a low forecast of $11.00. Should I buy or sell Verve Therapeutics stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last year. There are currently 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" VERV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VERV, but not buy additional shares or sell existing shares. Does Verve Therapeutics's stock price have much upside? According to analysts, Verve Therapeutics's stock has a predicted upside of 30.92% based on their 12-month stock forecasts. Has Verve Therapeutics been downgraded by Wall Street analysts recently? Over the previous 90 days, Verve Therapeutics's stock had 6 downgrades by analysts. What analysts cover Verve Therapeutics? Verve Therapeutics has been rated by research analysts at BMO Capital Markets, Canaccord Genuity Group, HC Wainwright, Jefferies Financial Group, Lifesci Capital, and William Blair in the past 90 days. Do Wall Street analysts like Verve Therapeutics more than its competitors? Analysts like Verve Therapeutics less than other "medical" companies. The consensus rating for Verve Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VERV compares to other companies. Stock Forecasts and Research Tools Related Companies Beam Therapeutics Stock Forecast Lantheus Stock Forecast Arcellx Stock Forecast Akero Therapeutics Stock Forecast Zai Lab Stock Forecast Mirum Pharmaceuticals Stock Forecast MoonLake Immunotherapeutics Stock Forecast Protagonist Therapeutics Stock Forecast Apellis Pharmaceuticals Stock Forecast Metsera Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:VERV) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access